Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05701995 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting
A Phase 4 study of Psoriasis, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 4
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT05701995: Completed Phase 4 study of Psoriasis, sponsored by Bristol-Myers Squibb.
NCT05701995 is a Phase 4 study of Psoriasis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 180 participants, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05701995, a Phase 4 study of Psoriasis, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
Primary Outcome
Dermatology Life Quality Index (DLQI) is a participant-reported Quality of Life (QoL) survey which consists of 10 questions concerning symptoms and feelings, daily activities, leisure, work, school, personal relationships, and treatment during the last week. Each question is scored on a 4-point scale: 0=not at all 1. a little 2. a lot 3. very much The scores are added up to give a total score between 0 and 30. A lower total score means a better quality of life.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Deucravacitinib
Study Locations (20)
California
- Local Institution - 0004 - Bakersfield
- Local Institution - 0009 - Sacramento
- Local Institution - 0022 - San Diego
Florida
- Local Institution - 0027 - Brandon
- Local Institution - 0016 - Coral Gables
- Riverchase Dermatology - Pembroke Pines
Illinois
- Local Institution - 0007 - Rolling Meadows
- Local Institution - 0025 - Skokie
- Local Institution - 0036 - Springfield
Arizona
- Local Institution - 0006 - Phoenix
- Local Institution - 0034 - Scottsdale
Georgia
- Local Institution - 0037 - Atlanta
- Local Institution - 0020 - Snellville
Michigan
- Local Institution - 0010 - Auburn Hills
- Local Institution - 0002 - Waterford
Arkansas
- Local Institution - 0015 - North Little Rock
Colorado
- Local Institution - 0030 - Centennial
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2023-01-31 |
| Est. Completion | 2025-05-29 |
| Phase | Phase 4 |
What the finished NCT05701995 record still lists
NCT05701995 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05701995 names 20 study sites across 11 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT05701995 about?
NCT05701995 is a clinical study titled "A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting". The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
What is the current status of trial NCT05701995?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 180 participants. The study started on 2023-01-31. Estimated completion is 2025-05-29.
What conditions does trial NCT05701995 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT05701995?
The interventions under investigation include: Placebo (OTHER), Deucravacitinib (DRUG).
Who is sponsoring clinical trial NCT05701995?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05701995 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05701995's enrollment target sits among peer trials
180 42nd of 125 higher than 84 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
RECRUITING · Phase 4
-
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
-
Taltz in Combination With Enstilar for Psoriasis
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI